Abstract LB-49: ABC transporters in the blood-brain barrier limit the brain penetration of the PARP inhibitor ABT-888
Olaf van Tellingen(The Netherlands Cancer Institute), Jan H. Beumer(Johns Hopkins University), Susan M. Christner(Utrecht University), Mark C. de Gooijer(Manchester Academic Health Science Centre), Jos H. Beijnen(The Netherlands Cancer Institute)
Cited by 1
Related Papers
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
|PubMed|2002|507
Clinical Pharmacokinetics of Cyclophosphamide
|Clinical Pharmacokinetics|2005|451
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
|The Lancet Oncology|2018|419
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.
|Journal of Clinical Oncology|1993|313